Get the Stockscreener App
21.12
0.80%
-0.17
Pre-market:
21.60
0.48
+2.27%
Seaport Therapeutics Inc stock is traded at $21.12, with a volume of 105.74K.
It is down -0.80% in the last 24 hours and down -12.29% over the past month.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.
See More
Previous Close:
$21.29
Open:
$21.08
24h Volume:
105.74K
Relative Volume:
0.60
Market Cap:
$1.13B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-29.34
EPS:
-0.7198
Net Cash Flow:
-
1W Performance:
-3.21%
1M Performance:
-12.29%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$19.93
$21.37
1-Week Range:
$19.93
$23.10
52-Week Range:
$14.85
$28.38
Seaport Therapeutics Inc Stock (SPTX) Company Profile
Name
Seaport Therapeutics Inc
Sector
Industry
Phone
617-807-4062
Address
6 TIDE STREET, BOSTON
Compare SPTX vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPTX
Seaport Therapeutics Inc
|
21.12 | 1.13B | 0 | 0 | 0 | -0.7198 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Seaport Therapeutics Inc Stock (SPTX) Latest News
SPTX: Pivotal phase II trials for novel neuropsychiatric drugs advance, backed by robust funding - TradingView
Seaport Therapeutics at TD Cowen summit: pipeline gains momentum By Investing.com - Investing.com Canada
Seaport Therapeutics, Inc. (SPTX) stock price, news, quote and history - Yahoo Finance UK
Seaport Therapeutics, Inc.(NasdaqGS: SPTX) added to S&P Global BMI Index - marketscreener.com
Seaport Therapeutics, Inc.(NasdaqGS:SPTX) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
Seaport Therapeutics (NASDAQ:SPTX) Shares Gap UpHere's What Happened - MarketBeat
Seaport Therapeutics to Participate in September Investor Conferences - Business Wire
The Manufacturers Life Insurance Company Acquires New Stake in Seaport Therapeutics, Inc. $SPTX - MarketBeat
Analysts Conflicted on These NA Names: SailPoint, Inc. (SAIL) and Seaport Therapeutics, Inc. (SPTX) - theglobeandmail.com
Analysts Offer Insights on NA Companies: Seaport Therapeutics, Inc. (SPTX), Navan, Inc. Class A (NAVN) and International Business Machines (IBM) - The Globe and Mail
Seaport Therapeutics (NASDAQ:SPTX) Stock Price Up 4.6%Should You Buy? - MarketBeat
HC Wainwright Reaffirms Buy Rating for Seaport Therapeutics (NASDAQ:SPTX) - MarketBeat
symbol__ Stock Quote Price and Forecast - cnn.com
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers - biospace.com
Seaport Therapeutics at citigroup’s biopharma back to school summit 2026: platform push - Investing.com Canada
Seaport Therapeutics reports positive phase 1 trial results - investing.com
Seaport Therapeutics, Inc.Common Stock (Nasdaq:SPTX) Stock Quote - FinancialContent
Seaport Therapeutics reports positive phase 1 trial results By Investing.com - Investing.com Canada
PureTech Says Seaport Therapeutics Reports Positive Phase 1 Driving Trial Results for GlyphAllo - TradingView
RCSPureTech Health PLCPRTC's SPTX: New Positive Phase 1 GlyphAllo Data - TradingView
Seaport Therapeutics Says GlyphAllo Shows no Next-Morning Driving Impairment in Phase 1 Trial - marketscreener.com
Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers - Business Wire
Citadel Advisors LLC Takes Position in Seaport Therapeutics, Inc. $SPTX - MarketBeat
Braidwell LP Takes $10.86 Million Position in Seaport Therapeutics, Inc. $SPTX - MarketBeat
Seaport Therapeutics, Inc. (NASDAQ:SPTX) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Alyeska Investment Group L.P. Makes New $1.63 Million Investment in Seaport Therapeutics, Inc. $SPTX - MarketBeat
Seaport Therapeutics, Inc. Common Stock (NASDAQ: SPTX) Stock Price, News & Analysis - kalkine.ca
Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference - BioSpace
Trv Gp Vi LLC Acquires New Shares in Seaport Therapeutics, Inc. $SPTX - MarketBeat
Seaport Therapeutics (NASDAQ:SPTX) Stock Price Down 5.2%Here's Why - MarketBeat
Seaport Therapeutics (NASDAQ:SPTX) Now Covered by Analysts at JonesTrading - MarketBeat
Seaport Therapeutics (NASDAQ:SPTX) Sets New 52-Week HighHere's Why - MarketBeat
Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO - 24/7 Wall St.
Seaport Therapeutics' (SPTX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
H.C. Wainwright reiterates Seaport Therapeutics stock rating at buy By Investing.com - Investing.com Canada
Selvaraju Reiterates Buy on Seaport, Citing Differentiated Neuropsychiatry Pipeline and Unchanged $50 Price Target - TipRanks
Seaport Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | SPTX | US81221K1088 - marketscreener.com
Seaport Therapeutics (NASDAQ:SPTX) Reaches New 52-Week HighHere's What Happened - MarketBeat
Seaport Therapeutics Inc. (SPTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
PureTech Health (SPTX holder) discloses 31.2% Seaport Therapeutics stake - Stock Titan
Stifel Maintains Seaport Therapeutics(SPTX.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Top Seaport Therapeutics (SPTX) Competitors 2026 - MarketBeat
Seaport Therapeutics (SPTX) Stock Chart and Price History 2026 - MarketBeat
Seaport Therapeutics: A Development-Arbitrage Platform With Two Layers Of Validation - Seeking Alpha
Seaport Therapeutics (SPTX) Institutional Ownership 2026 - MarketBeat
Seaport Therapeutics, Inc. (NASDAQ:SPTX) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
HC Wainwright Has Negative Outlook for SPTX FY2026 Earnings - MarketBeat
Seaport Therapeutics Inc Stock (SPTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Seaport Therapeutics Inc Stock (SPTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ARCH Venture Partners XII, LLC | 10% Owner |
May 04 '26 |
Buy |
18.00 |
1,100,000 |
19,800,000 |
6,294,951 |
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):